Unlike traditional scFvs, TSHR is a G protein-coupled receptor with four extracellular domains that specifically bind pathogenic autoantibodies to its N-terminal (21–413 amino acids), offering a novel approach for treating Graves’ disease. This evidence concerns the gene TSHR and Graves disease.